Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aslan Pharmaceuticals (ASLN – Research Report), Prime Medicine, Inc. (PRME – Research Report) and HealthStream (HSTM – Research Report).
Aslan Pharmaceuticals (ASLN)
Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Aslan Pharmaceuticals today and set a price target of $15.00. The company’s shares closed last Tuesday at $1.20, close to its 52-week low of $1.12.
According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of
Aslan Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $15.67, which is a 1205.8% upside from current levels. In a report issued on October 16, H.C. Wainwright also reiterated a Buy rating on the stock with a $17.00 price target.
See today’s best-performing stocks on TipRanks >>
Prime Medicine, Inc. (PRME)
BMO Capital analyst Kostas Biliouris initiated coverage with a Buy rating on Prime Medicine, Inc. yesterday and set a price target of $19.00. The company’s shares closed last Tuesday at $6.85, close to its 52-week low of $6.11.
According to TipRanks.com, Biliouris is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Prime Medicine, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $20.50.
HealthStream (HSTM)
Canaccord Genuity analyst Richard Close maintained a Hold rating on HealthStream yesterday and set a price target of $24.00. The company’s shares closed last Tuesday at $25.20.
According to TipRanks.com, Close is a 5-star analyst with an average return of
HealthStream has an analyst consensus of Moderate Buy, with a price target consensus of $24.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ASLN:
- ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
- ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress
- Aslan Pharmaceuticals presents data from Phase 2b study of eblasakimab
- ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress
- ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
